Breaking News, Collaborations & Alliances

IMIDomics, BMS Expand Partnership to Advance IMID Treatment

Leveraging IMIDomics’ clinical network and resources, the companies aim to select the right drug for the right patient at the right time.

IMIDomics, a drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), has expanded its strategic collaboration with Bristol Myers Squibb to accelerate research and development aimed at treating IMID patients. In 2016, IMIDomics entered into a strategic partnership with BMS to harness their clinical and molecular database, and multidimensional analysis concentrated on IMIDs such as ulcerative colitis, Crohn’s disease, psoriatic arthritis, rheumatoi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters